Ovid Therapeutics (OVID) Cash & Current Investments (2016 - 2026)

Ovid Therapeutics has reported Cash & Current Investments for 11 years, with the latest figure at $155.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 261.71% year-over-year to $155.5 million; the trailing twelve-month figure through Mar 2026 stood at $155.5 million (up 261.71% YoY), and the FY2025 full-year result was $69.1 million, up 30.23% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $155.5 million, up from $69.1 million in the prior quarter.
• The five-year high for Cash & Current Investments was $166.7 million in Q1 2022, with the low at $25.5 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $93.7 million across 5 years, with a median of $88.9 million in 2024.
• Annual changes were most pronounced in 2025 — Cash & Current Investments slumped 59.61% — and 2026, when it jumped 261.71%.
• Ovid Therapeutics' Cash & Current Investments stood at $126.1 million in 2022, then dropped by 16.1% to $105.8 million in 2023, then tumbled by 49.85% to $53.1 million in 2024, then jumped by 30.23% to $69.1 million in 2025, then soared by 125.01% to $155.5 million in 2026.
• The last three Cash & Current Investments figures came in at $155.5 million (Q1 2026), $69.1 million (Q4 2025), and $25.5 million (Q3 2025), per Business Quant data.